Navigation Links
The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Date:8/19/2007

l benefit response (CBR), time to progression (TTP), duration of response (DOR), progression-free survival, and best ORR throughout the study. Patients enrolled in the trial will receive carfilzomib twice weekly for three weeks every 28 days.

"Based on promising laboratory and clinical data, we believe that carfilzomib holds promise in treating patients with multiple myeloma, including those for whom other treatments have failed," said Sundar Jagannath, M.D., Saint Vincent's Comprehensive Cancer Center, where the first patient was enrolled. "We are excited to bring this compound into the MMRC as a critical step in bringing this new treatment to patients."

In the coming weeks, the MMRC and Proteolix will also begin enrolling an open-label, single-arm, Phase 2 study of carfilzomib in patients with relapsed multiple myeloma, who will be stratified by bortezomib (Velcade(R), Millennium Pharmaceuticals, Inc.) history.

About Carfilzomib

Carfilzomib is a structurally- and mechanistically-novel proteasome inhibitor that exhibits a high level of selectivity for the unique N-terminal threonine active sites within the proteasome. Carfilzomib is similar to bortezomib in that it is a potent inhibitor of the proteasome chymotrypsin- like activity, but unlike bortezomib, carfilzomib has shown minimal cross- reactivity with the other catalytic sites within the proteasome or across other protease classes. Phase 1 clinical studies confirmed that patients who have relapsed or progressed following multiple therapies can still achieve durable anti-tumor responses with carfilzomib. In addition to the two Phase 2 single-agent trials in myeloma and ongoing studies in lymphoma, a clinical trial in solid tumors and a trial exploring carfilzomib in combination with an FDA-approved agent will be initiated by the end of the year.

"The Phase 1 data consistently demonstrate carfilzomib anti-tumor activity in myeloma patients who have failed multiple lines of therapy,
'/>"/>

SOURCE Proteolix

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Gentiums Defibrotide Seen as Active in Multiple Myeloma
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
10. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
11. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2009)... INDIANAPOLIS, Jan. 7 E...ay that it received a complete response letter fro... olanzapine long-acting,injection (LAI) for acute...ults. Lilly is continuing to work with the agency ...DA does not require any additional clinical trials...
(Date:1/7/2009)...EDERICK, Md., Jan. 7 ImQuest Life ... of an IND application to the Food and Drug Admini...ir lead pyrimidinedione HIV inhibitor IQP-0410. Im... in the first quarter of 2009. IQP-0410 is a novel...cts as a nonnucleoside reverse transcriptase inhib...
(Date:1/7/2009)... OXFORD, England, January 7 Circa...ocused on allergy and critical care, today,announ...ieved in 2008 with,its ToleroMune(R) anti-allergy...t recruitment for a further phase II clinical tria... Canada, has recruited 120 patients with confirmed...
(Date:1/6/2009)...MMACK, N.Y., Jan. 6 In recent cont...University of Memphis , scientists found that the ..., is the first and only proven ingredient to incre...by increasing blood nitrate/nitrate (NOx) in human...or and enables an increase in blood flow to the sk...
Breaking Medicine Technology:FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 2FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 3FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 4FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 5FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 6ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 3US Testing Proves Glyc'n Go(TM) Increases NO in the Blood Stream 2Environment plays key role in childrens readiness for school 6386 1Environment plays key role in childrens readiness for school 6386 2Living arrangements health and well being 3A A European perspective 6384 1Living arrangements health and well being 3A A European perspective 6384 2Family conditions may affect when girls experience puberty 1231 1Family conditions may affect when girls experience puberty 1231 2New south Florida nursery to focus on staghorn corals 1229 1New south Florida nursery to focus on staghorn corals 1229 2
(Date:1/8/2009)...s it lowered bad cholesterol more effectively than...ews) -- After nearly a year of review, U.S. health...ontinued use of the controversial cholesterol-lowe...inistration said there was no significant differen...king Vytorin and patients taking the drug Zocor. ,...
(Date:1/8/2009)...Announced Acquisition in 2009 Continues Growth Tre...ire-FirstCall/ -- IPC The Hospitalist Company, Inc...t physician group practice company, announced toda... Midwest Acute Care Consultants, Inc. (MACC) in St...inued expansion in the St. Louis market, where IPC...
(Date:1/8/2009)...d be used when assessing traditional risk factors,...hDay News) -- Two molecular signs -- or "biomarker...on when trying to assess a person,s risk of stroke... very low risk, adding these markers does not chan...Nambi, a cardiologist at the Methodist DeBakey Hea...
(Date:1/8/2009)...gnetically-navigated guidewire provides minimally-..., , AUSTIN, Texas, Jan. 8 The H...the world to use the new Stereotaxis RF PowerAsser...onic total occlusions (CTOs), or complete blockage..., Austin Heart interventional cardiologist, Frank...
Breaking Medicine News(10 mins):Health News:FDA Backs Cholesterol Drug Vytorin 2Health News:IPC The Hospitalist Company Acquires Missouri Practice Group 2Health News:Inflammation Markers May Help Predict Stroke Risk 2Health News:Inflammation Markers May Help Predict Stroke Risk 3Health News:Heart Hospital of Austin First in World to Use New Device for Blocked Arteries 2
...sity College London (UCL), regular consumption of .../ They conducted a study that was published in th... who drank black tea 4 times a day for 6 weeks had...rtisol than the control group that drank a false t...
...c places such as offices, restaurants and café’s m...n// made by a panel consisting of members from the...tated that about 3000 to 5000 people exposed to pa... illness. This is an unacceptable situation. Howev...
...g terms such as "frequent flyers" and "bed-blocker... tsar. The national director for patients and the ...ted blame to patients and should be avoided, accor...Medicine journal. The NHS was accused of commonly...
...of an epidemic in California which has been linked...oody stools in those affected by this organism, in...ihilate the source of E coli in spinach. The E c... crops by manure commonly used as a fertilizer b...
Other Medicine News:Health News:Black tea alleviates stress 2Health News:NHS Reprimanded for Demeaning Words 2
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
Medicine Products: